arteriolar bleeding by pressure, ligature and conventional procedures
is ineffective or impractical.
-- The launch of the company's V-Link Luer-activated device (LAD) with
VitalShield protective coating, the first needleless IV connector
containing an antimicrobial coating. The protective coating has been
shown to kill on average 99.9 percent of specific common pathogens
(infection-causing microorganisms) within the device that are known to
cause catheter-related blood stream infections, including the highly
treatment-resistant bacteria called methicillin-resistant
Staphylococcus aureus, or MRSA.
-- The announcement of preliminary results of a Phase I/II clinical trial,
in which subcutaneous infusion (under the skin) of GAMMAGARD LIQUID
[Immune Globulin Intravenous (Human)] (IGIV) with Enhanze(TM)
Technology enabled administration of a full monthly dose via a single
site to patients with primary immunodeficiency (PID).
Second Quarter and Full-Year 2008 Outlook
Baxter also announced today that it is raising its earnings outlook for full-year 2008. The company continues to expect sales growth, excluding the impact of foreign exchange, of 5 to 6 percent. Excluding Transfusion Therapies from both 2007 and 2008 and excluding foreign exchange, the company expects sales growth of approximately 6 to 7 percent. Baxter now expects to achieve earnings per diluted share of $3.18 to $3.24, before any special items, and cash flow from operations of approximately $2.6 billion. Previously, the company had provided earnings guidance of $3.10 to $3.18 per diluted share, excluding special items, and expected to generate cash flow from operations of more than $2.5 billion.
For the second quarter of 2008, Baxter expects sales growth of 4 to 5
percent, excluding the impact of foreign exchange, and earnings
|SOURCE Baxter International Inc.|
Copyright©2008 PR Newswire.
All rights reserved